Reason for request

Re-assessment of the actual benefit (AB) in accordance with Article R 163-21 of the social security code.

-


Clinical Benefit

Low

The actual benefit of GENOTONORM in children born small for gestational age with a birth weight and/or length of < -2 SD who failed to show catch-up growth (growth rate < 0 SD during the last year) by 4 years of age or later and with growth failure (current height less than or equal to -3 SD and parental adjusted height < -1 DS) is low.

Substantial

The actual benefit of GENOTONORM in Turner syndrome is substantial.

The actual benefit of GENOTONORM in chronic renal disease is substantial.

The actual benefit of GENOTONORM in Prader-Willi syndrome is substantial.


Clinical Added Value

minor

GENOTONORM provides about a minor improvement in actual benefit (IAB IV) in the treatment of Turner syndrome and chronic renal disease.

no clinical added value

GENOTONORM does not provide about an improvement in actual benefit (IAB V) in the therapeutic strategy in children born small for gestational age.


Contact Us

Évaluation des médicaments

See also